Heart failure occurs in 1% of the UK adult population yet represents 5% of all hospital admissions, according to the 2008/09 National Heart Failure audit (http://www.ic.nhs.uk/ webfiles/publications/002_Audits/NHS_IC_ HEART_FAILURE_AUDIT_13-12-10.pdf ). The 3 month readmission rate is as high as 30% and 30% of patients admitted will die within 1 yr of discharge. Medical therapies, such as angiotensin-converting enzyme inhibitors, b-blockers, diuretics, inotropic agents, and anti-arrhythmics represent the usual care, but for patients with end-stage heart failure the only effective treatment is surgical intervention.
In addition, cardiogenic shock associated with acute myocardial infarction, postcardiotomy and cardiomyopathies carries a high mortality if treated by conservative means alone.
Ventricular assist devices (VADs) are mechanical systems that reduce the workload of the heart, permitting the ventricle to rest, whilst maintaining cardiac output and perfusion of vital organs. They have subsequently gained popularity in both acute and chronic heart failure as potentially life-saving treatment modalities.
Indications for VADs
VADs can be used to support the left ventricle (LVAD), the right ventricle (RVAD), or both (BIVAD). They are attached to the heart through cannulae that allow blood to enter a pumping chamber from which it is ejected into the systemic, pulmonary circulation, or both. The indications for such devices are described below.
Acute heart failure
Short-term rescue devices are a bridge to recovery, indicated for acute cardiogenic shock, for example, myocardial infarction, postcardiotomy, viral cardiomyopathies or inadequate preservation of donor heart after cardiac transplantation. In this setting, BIVAD support is often needed. The LVAD typically inserts from the left atrium to the ascending aorta and RVAD from the right atrium to the main pulmonary artery, via sternotomy. Much like a cardiopulmonary bypass (CPB) circuit, they are extra-corporeal in design with examples including the Levitronix Centrimag (Fig. 1A) and Abiomed AB5000. Insertion is straightforward, translating to low operative risk but offset against limited ambulation after operation and the need for continual intensive care support. Alternatively, peripheral, venoarterial extracorporeal membrane oxygenation (ECMO) 1 has the advantage of supporting both the heart and lung whilst avoiding the need for sternotomy for implantation and explantation. It is ideal for the reversible ischaemia of myocardial stunning, where recovery is often seen within 2-5 days. However, ECMO is a resource-intense, highly technical and demanding therapy and requires meticulous attention in managing cannulae positions, distal limb perfusion and patient oxygenation. It is unsuitable as a longer-term rescue therapy. The cost of hardware for short-term devices is comparatively inexpensive and akin to 1 -2 days intensive care stay.
Chronic heart failure
Coronary artery disease is the most common cause of chronic heart failure and often associated with hypertension. Ischaemic and dilated cardiomyopathies form another group that require surgical intervention. Heart transplantation remains the most successful long-term surgical treatment for patients with advanced heart failure refractory to medical therapy. However, limited organ availability and waiting times of .6 months have led to VADs becoming an established treatment modality as a bridge to transplantation. The device supports the patient and improves physiology until a donor becomes available. Because devices are predominantly intracorporeal, discharge from intensive care and hospital are possible, improving quality of life when compared with short-term devices.
Key points
Ventricular assist devices are surgically placed mechanical devices used for the treatment of severe heart failure, which can support the left ventricle (LV), right ventricle (RV), or both.
They can be used as a bridge to either recovery, cardiac transplantation, or as long-term destination therapy.
Continuous-flow devices have largely superseded pulsatile-flow devices.
Preservation and protection of RV function is of paramount importance in ensuring LV only support.
Bleeding, thromboembolism, infection, and device failure are the major complications of use.
The use of VADs as destination therapy to support patients with end-stage heart failure who are unsuitable candidates for cardiac transplantation is now an acceptable and viable therapy, although not currently routine in the UK.
The aim for long-term therapy is for LVAD support alone. RV failure is commonly from pulmonary hypertension secondary to LV failure and improves after LVAD implantation. However, a small percentage of patients develop true biventricular failure and require long-term BIVAD support. RV failure manifests with chamber dilatation in systole and diastole, high atrial pressures (.20 mm Hg), reduced RV stroke work and severe tricuspid regurgitation. BIVAD patients have a worse prognosis because of increased complexity of device insertion and management, and in addition, only LVADs have been designed for long-term support (Table 1 ). The options are a hybrid approach, utilizing a long-term LVAD and short-term RVAD in the hope that the RV recovers or alternatively, a total artificial heart must be considered. 2 For longterm devices, hardware is 20 -30 times more expensive than shortterm devices.
History and classification

First-generation devices
These mimic normal cardiac function and circulation by providing pulsatile blood flow at physiological rates. The energy source used to eject blood from the pumping chamber may be pneumatic, hydraulic, or by mechanical pusher plate. These mechanisms produce audible pump operation. Although successful, their use is associated with a significant morbidity, because of extensive surgical dissection, large pump, and large diameter percutaneous lead for venting of air. Durability beyond 2 yr is rare and operations for device exchange carry high risk.
Second-generation devices
Flow is continuous and non-pulsatile, which reduces the pump size and the need for external venting. The important distinguishing feature is the bearings' design. The term secondgeneration describes rotary pumps, typically with axial blood flow, which have an internal rotor within the blood path that is suspended by contact bearings. These bearings are generally mechanical (ball, ruby, or fluid design). They are essentially a propeller in a pipe. Spinning of the internal rotor and flow generation is by magnetic coupling of the rotor magnet to an external rotor. An example of a popular device, the Heartmate II can be seen in Figure 1B .
Third-generation devices
These rotary pumps have non-contact bearings (or bearingless) and utilize centrifugal blood flow, incorporating either magnetic or hydrodynamic levitation of an internal impeller. The impeller is typically a short cylinder with a fluid inlet and vanes for radial Ventricular assist devices flow. Impeller rotation achieves blood flow through magnetic coupling to the pump motor. An example of a popular device, the Heartware, can be seen in Figure 1C . These devices have several unproven advantages over older designs. Levitation of the impeller eliminates contact bearings, improving reliability and durability. Greater blood flow can be achieved around the impeller, which reduces thrombus formation and the intensity of antithrombotic therapy required. Greater pump response to changes in blood flow reduces the risk of suction events in the case of reduced blood delivery into the device.
A summary of all devices in current use can be found in Table 1 .
Patient selection
Patient selection, preoperative optimization and timing of implantation are major determinants of success. Contraindications to VAD insertion are listed in Table 2 . assistance. 4 Preoperative inotropic support with phosphodiesterase inhibitors (e.g. milrinone) and intra-aortic balloon counter-pulsation are commonly used to aid RV function. (iii) Aortic valve: aortic insufficiency can be catastrophic and must be identified or excluded. Even mild regurgitation is problematic as the gradient between the mean arterial pressure and LV end-diastolic pressure will be much greater after VAD insertion. This worsens aortic regurgitation and produces circulation of blood from VAD to the aorta to LV to VAD, thus impeding true cardiac output. Valve replacement or permanent valve closure must be undertaken in such circumstances pre-device insertion. (iv) Mitral valve function: mitral stenosis must be corrected or replaced at the time of surgery, but mitral regurgitation often improves once the LV is decompressed. (v) Intracardiac shunts: patent foramen ovale and atrial septal defects must be identified and closed before mechanical support is instituted to prevent a right-to-left shunt, which contributes to systemic hypoxaemia. This shunt manifests from raised cardiac output and venous return to the right atrium, with low left-sided pressures from blood flow into the LVAD.
Systemic considerations
Lowering pulmonary vascular resistance optimizes RV function and prevents hepatic congestion and is achieved with aggressive diuretic usage. Diuretics can worsen renal function and an estimated glomerular filtration rate of ,50 ml min 21 m 22 is associated with poor outcome. 5 Renal impairment secondary to low cardiac output often improves post-device insertion. Malnutrition and impaired immunity are commonly encountered in the preoperative patient, thus dietary intervention is warranted. Conversely, VADs are capable of meeting the high metabolic demands of obese candidates and thus a higher BMI confers a lower risk. 6 Hepatic dysfunction, such as cirrhosis and portal hypertension, is associated with poor outcomes after LVAD implantation. 7 Evidence of liver disease should be resolved with liver biopsy before implantation. Patients are considered cautiously for an assist device if aminotransferases are three times normal, INR .1.5, or total bilirubin .5 mg dl 21 . Hepatic congestion may be a marker of impaired RV function and increases the risk of biventricular support. As patients are often warfarinized, administration of vitamin K to normalize INR levels and stopping anticoagulant and anti-platelet agents before operation is recommended.
Other considerations
Other factors contributing to successful outcome include careful selection of device type and the skill, experience, and judgement of the implanting team. Patient and family mental attitude, compliance with care, and ability to operate and care for external system components all warrant consideration in the selection process. 
Anaesthesia for VAD insertion
Induction and maintenance
Induction must prevent haemodynamic decompensation from reduced preload and contractility and is best performed inside the operating theatre with titrated increments of induction agents and inotropic support. Rapid sequence induction is modified to continue ventilation with cricoid pressure thus avoiding hypoxic and hypercarbic pulmonary hypertension. Inhalation or i.v. anaesthesia is suitable, but nitrous oxide best avoided. External defibrillation pads are attached. Antibiotic prophylaxis is customized to the institution's pathogenic flora and includes broad-spectrum grampositive bacterial and anti-fungal cover. Body warming devices are used to maintain normothermia. Surgical access is commonly via median sternotomy, but left thoracotomy with lung isolation via a double-lumen endotracheal tube is an option. Bleeding is common so aprotinin anti-fibrinolysis and cell salvage are routinely used. Full heparinization is required, irrespective of preoperative coagulation.
Perioperative period
TOE is used to exclude valve lesions, shunts and intracardiac thrombi as discussed above. CPB is generally but not universally used for placement of inflow cannulae within the ventricle, but duration can be minimized by tunnelling the percutaneous lead and completing the outflow cannula anastomosis before instituting bypass. Inflow cannulae are directed posteriorly towards the mitral valve to prevent obstruction. Before VAD activation, all air should be removed and the heart filled with blood. Deairing is via backflow of blood from the aorta to a Luer lock connection on the outflow cap and by elevating the LV apex. The VAD is initiated at low speed with a cross-clamp on the outflow cannula and a needle vent. CPB flow is then reduced followed by removal of the graft cross-clamp. The LV should be full and off CPB before the pump speeds are increased to avoid entraining air into the system, which Ventricular assist devices is further minimized by flooding the surgical field with saline or carbon dioxide.
Weaning from CPB
Atelectatic lung is expanded before weaning bypass to prevent Valsalva-induced hypotension. CPB weaning concerns are from RV failure, pulmonary hypertension, systemic vasodilatation, and bleeding. TOE is vital for deairing, RV assessment, and to check cannulae positions and flow. RV dysfunction can be difficult to predict, thus monitoring and prophylaxis against right heart failure must be instituted in all cases before separation from bypass, using inhaled nitric oxide, i.v. nitrates and phosphodiesterase inhibitors. RV dysfunction results in chamber dilatation and leftward ventricular septal deviation on TOE, predicting imminent failure. Atrial or AV sequential pacing is useful to maintain adequate cardiac output. Protamine must be used to reverse heparinization but can worsen RV function and cause pulmonary hypertension.
Postoperative complications
The immediate postoperative management of VADs presents a real challenge for both surgeon and intensivist. Continuous TOE, left in situ from the operating theatre, assesses filling of both ventricles, manages RV dysfunction and screens for cardiac tamponade.
The most common problems encountered are the following:
(i) Bleeding: This is the most frequent complication after VAD implantation and coagulopathy is common. Minimizing CPB times, meticulous surgical technique, autologous blood transfusion, and normothermia are standard. Early re-exploration reduces the excessive use of blood and associated products, which risk transfusion-related lung injury. Platelet consumption via the device and the risk of spontaneous intracerebral haemorrhage translate into early platelet transfusion. TEG and laboratory results guide blood products' administration. (vi) Haemodynamic instability: Post-LVAD insertion, the interventricular septum is entrained leftwards towards the inflow cannula when the ventricles are underfilled. This differs from septal deviation seen with RV failure or high pump speeds. TOE is crucial to determine the need for further fluid challenges and adjustment of pump speeds. (vii) Gastrointestinal and hepatic dysfunction: First-generation VADS, in the intraperitoneal position produced frequent upper GI pressure symptoms on the stomach and intestines, but this is rarely seen with second-and third-generation devices. Ileus is common and managed with prokinetics. Enteral feeding is advocated as soon as gut function is resumed. Liver dysfunction is common in patients with chronic heart failure. Close monitoring of liver enzymes and withdrawal of hepatotoxic drugs limits further damage. Warfarin therapy should be monitored closely with impaired liver synthetic function. (viii) Infection: Antibiotic prophylaxis is continued according to hospital infection control policy. Preoperative malnutrition and invasive support and also the VAD itself contribute to postoperative infections.
Outpatient management
Successful long-term VAD management depends on comprehensive care from a multidisciplinary team, including patient, family, and care workers, with education and support being key components of outpatient survival. There are excellent outcomes for VAD patients who are managed in an outpatient capacity. 8 
Medical management
Medical management includes INR optimization with warfarin (varies by device, typically 1.5-2.5). Hypertension reduces VAD support and increases the risk of cerebral events and thus must be controlled. Aspirin is commonly prescribed for its anti-platelet action. Haemorrhagic complications are commoner (22%) than thrombotic events (3.3%), suggesting that patients are at times over-coagulated. Of these, spontaneous intracerebral haemorrhage is by far the most serious (incidence 1-1.7%). Fluid balance can also be a challenge to avoid the risks of both fluid overload and dehydration (Table 3) .
Device management
Device management is vitally important. alarms must be learnt and appropriate actions be taken. Meticulous percutaneous lead care and immobilization as well as exit site wound management can reduce the number of hospital readmissions and risk of further procedures.
Psychological management
There is a wide range of user manual support and device documentation that families must be knowledgeable of. There must be a 24-h contact support network to cover all emergencies, questions, and technical support.
Anaesthesia for VAD patients
Anaesthesia for non-cardiac procedures in VAD patients can be performed by general anaesthetists, with cardiac support from perfusionist or VAD nurse, preferably in a VAD centre. Patients may be from intensive care units but are often ambulatory and in good condition. Table 3 highlights optimization of patients to ensure the safest passage through the perioperative period. Anticoagulation must be continued but balanced against the bleeding risk for the surgery proposed. A possible solution is the titrated administration of freshfrozen plasma without fully reversing anticoagulation plus the use of antifibrinolytics, for example, tranexamic acid. Strict aseptic technique and prophylactic antibiotics are required for all invasive procedures. Invasive haemodynamic monitoring is not mandatory and may prove challenging, with arterial cannulation often necessitating ultrasound guidance in the absence of pulsatile flow. Central venous and pulmonary artery monitoring are warranted for surgery with large fluid shifts, as is TOE. The RV needs meticulous attention to prevent sudden failure and must be supported. Bipolar electrocautery is unlikely to interfere with VAD operation. Drivelines and cannulae should be excluded from the surgical field as fluid contamination may lead to plastic degradation and device malfunction. Effective teamwork is the key to successful outcome of these patients.
Recovery, weaning, and transplantation
Cardiogenic shock requiring VAD support is rare after cardiac surgery (,1%). Recovery is usually within 72 h but unlikely after 7 days; 20 -40% of this VAD group survive to hospital discharge. Similar figures are seen post-myocardial infarction. Recovery from acute myocarditis and non-ischaemic cardiomyopathy is less common, with 5-15% improving to explantation.
With VAD support, the heart can be volume offloaded, which limits deterioration in ventricular compliance from over-distension and reduces myocardial work. Reducing cardiac inflammation and sympathetic drive can prevent myocyte death and contractile dysfunction, promoting a return to normal cellular, electrical, neurohormonal and functional indices. 9 Short-term devices and ECMO Ventricular assist devices rely on these changes as recovery and explantation avoids upgrade to longer-term devices.
Reverse remodelling can be seen in chronic heart failure, with a chance for explantation but recovery after more than 2-3 months of VAD support is unlikely. Potential candidates for heart transplantation must be free from ventilatory support and potential recipients should meet all the usual selection criteria before transplantation is undertaken. Cardiac transplantation with VAD in situ is a highly skilled procedure because of the complexity of cannulae positions and thus femoral or axillary CPB is often instituted. The same haemodynamic considerations of VAD implantation must be applied. Previous aprotinin use risks anaphylaxis on subsequent exposure.
Weaning VAD support for explantation requires assessment of residual ventricular function with minimal pump support. Dobutamine stress echocardiography, cardiac output studies, peak VO 2 . 20 ml kg 21 min
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, and pulmonary artery wedge pressures guide the process. However, adequate reduction in pump flows for reliable native heart function is generally not possible, because of thrombus formation, thus explantation may fail.
The future
Design improvements in current VAD systems include totally implantable devices with transcutaneous energy transmission systems, which eliminate the need for a driveline insertion site and also designs allowing more acceptable side-effect profiles for thromboembolism, infection, and device failure. In addition, there are two total artificial hearts in clinical use, which involve explantation of the native heart and replacement with the device.
These are the CardioWest total artificial heart (Syncardia Inc.) and AbioCor (Abiomed Corporation). The latter organization also produces the Impella (Fig. 2) , one of a group of minimally invasive, catheter-based assist devices, which is inserted via the femoral artery, the tip of which crosses the aortic valve to rest in the LV and drive forward flow. Further detail on these devices can be found on their respective websites (www.syncardia.com, www. abiomed.com).
Finally, with more devices in production, there is a need for regulation. At present, all UK devices are regulated in accordance with rules set out by the National Commissioning Group of the NHS, with the equivalent body, INTERMACS controlling use in the USA.
